Mr. Dhillon has been the Chairman and Chief Executive Officer of Skye Bioscience since 2020. He has a 20-year track record as an executive and investor in the life sciences industry. Focusing on early-stage biotechs from start-up through clinical proof-of-concept, he has raised more than $500 million in capital and established multiple pharmaceutical partnerships. At Skye he has led a strategic acquisition of a novel peripheral CB1 inhibitor for obesity and other metabolic diseases, attracted specialist life science investors, and built out an expert board and management team. Mr. Dhillon was previously the co-founder and former CEO of OncoSec Medical, a developer of cancer immunotherapies and established collaborations with Merck and Genentech. Prior to Skye he was a managing director of a private San Diego-based pharmaceutical company where he launched an Asia-focused licensing business unit evaluating opportunities in Korea, China, Japan, and the US, and completed a partnership with BMS. He was formerly a director of the Emerald group of companies with responsibility for private equity investments, operations and business development. As Vice President, Finance and Operations, at Inovio Pharmaceuticals he completed licensing deals with Merck, Wyeth (now Pfizer) and Roche. Punit holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.